1. Home
  2. THW vs PRTA Comparison

THW vs PRTA Comparison

Compare THW & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

THW

abrdn World Healthcare Fund Shares of Beneficial Interest

HOLD

Current Price

$12.75

Market Cap

514.7M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.05

Market Cap

482.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THW
PRTA
Founded
N/A
2012
Country
US
US
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
514.7M
482.3M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
THW
PRTA
Price
$12.75
$9.05
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$18.86
AVG Volume (30 Days)
165.7K
364.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.75
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,183.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.80
$4.32
52 Week High
$13.19
$16.67

Technical Indicators

Market Signals
Indicator
THW
PRTA
Relative Strength Index (RSI) 54.69 48.06
Support Level $12.27 $8.80
Resistance Level $12.92 $9.23
Average True Range (ATR) 0.18 0.45
MACD 0.04 0.04
Stochastic Oscillator 79.23 79.70

Price Performance

Historical Comparison
THW
PRTA

About THW abrdn World Healthcare Fund Shares of Beneficial Interest

Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: